

**Supplemental eTable 1. Clinical presentation and final pathology in patients with incidental versus non-incidental mode of adrenal tumor discovery<sup>a</sup>**

<b>Variable</b>	<b>Incidentalomas</b>	<b>Non-incidentalomas</b>	<b>P value</b>
<b>N, %</b>	472 (67%)	233 (33%)	
<b>Sex</b>	249 (53%)	124 (53%)	0.90
Female, n (%)			
<b>Age at diagnosis</b>	60 (19-88)	54 (18-91)	<b>&lt;.001</b>
years, median (range)			
<b>Adrenal mass diameter</b>	5 (4-20)	6 (4-24.4)	<b>&lt;.001</b>
cm, median (range)			
<b>Diagnosis n (%)</b>			
Adrenocortical Adenoma (ACA)	184 (39%)	32 (14%)	<b>&lt;.001</b>
Other benign	104 (22%)	12 (5%)	
Pheochromocytoma	86 (18%)	72 (31%)	

Other malignant	61 (13%)	66 (28%)	
Adrenocortical carcinoma (ACC)	37 (8%)	51 (22%)	

<sup>a</sup>Range was defined as minimum to maximum value.

**Supplemental eTable 2. Clinical presentation of patients with adrenal tumors based on tumor size cutoff of 6 cm<sup>a</sup>**

	<b>Tumor size ≤ 6 cm</b>	<b>Tumor size &gt; 6cm</b>	<b>P value</b>
<b>N, %</b>	449 (64%)	256 (36%)	
<b>Sex</b>	234 (52%)	139 (54%)	0.60
Female, n (%)			
<b>Age at diagnosis</b>	60 (18-91)	56 (19-87)	<b>&lt;.001</b>
years, median (range)			
<b>Mode of discovery (n (%))</b>			
Incidental	326 (73%)	145 (57%)	<b>&lt;.001</b>
Hormone excess	62 (14%)	46 (18%)	
Cancer staging	43 (10%)	18 (7%)	
Other <sup>b</sup>	18 (4%)	47 (18%)	
<b>Adrenalectomy</b>	274 (61%)	183 (72%)	<b>.005</b>
yes, n (%)			

<b>Diagnosis, n (%)</b>			
Adenoma	194 (43%)	24 (9%)	<b>&lt;.001</b>
Pheochromocytoma	112 (25%)	46 (18%)	
Other malignant	76 (17%)	52 (20%)	
Other benign	53 (12%)	60 (23%)	
ACC	14 (3%)	74 (29%)	
<b>Bilateral</b>	74 (16%)	30 (12%)	<b>.08</b>
n (%)			

<sup>a</sup>Range was defined as minimum to maximum value

<sup>b</sup>Other: mass effect and B symptoms

Abbreviations used: ACC, adrenocortical carcinoma;